1. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. (26th February 2015) Authors: Mondi, A.; Fabbiani, M.; Ciccarelli, N.; Colafigli, M.; D'Avino, A.; Borghetti, A.; Gagliardini, R.; Cauda, R.; De Luca, A.; Di Giambenedetto, S. Journal: Journal of antimicrobial chemotherapy Issue: Volume 70:Number 6(2015:Jun.) Page Start: 1843 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort. Issue 3 (4th March 2019) Authors: Bavaro, D. F.; Di Carlo, D.; Zuccalà, P.; Bai, F.; Incardona, F.; Battisti, A.; Giachè, S.; Salomoni, E.; Gagliardini, R.; Di Giambenedetto, S.; Pecorari, M.; Zazzi, M.; De Luca, A.; Bezenchek, A.; Lo Caputo, S. Journal: Infectious diseases Issue: Volume 51:Issue 3(2019) Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SARS-CoV-2 infection does not induce HIV viral escape in the central nervous system: A case series. (December 2020) Authors: Pinnetti, C.; Vergori, A.; Agrati, C.; Castilletti, C.; Campioni, P.; Gagliardini, R.; Mondi, A.; Notari, S.; Amendola, A.; Cicalini, S.; Baldini, F.; Capobianchi, M.R.; Antinori, A. Journal: International journal of infectious diseases Issue: Volume 101(2020) Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗